Evidence map›Paper›PMID 40721790›Full record

ArticleMalaria journal2025

Subnational introduction of the RTS,S/AS01

Rose Jalang'o, Kwame Amponsa-Achiano, Mike Chisema, Keziah Malm, Lydiah Khalayi, Brenda Mhone, Wahjib Mohammed, Franklin Asiedu-Bekoe, Adam Haji, Josephine Njoroge and 13 more

Abstract read
In one paragraph

Article in Malaria journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Observational
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Rose Jalang'o *National Vaccines and Immunization Programme, Nairobi, Kenya.
Kwame Amponsa-Achiano *Expanded Programme on Immunization, Public Health Division, Ghana Health Service, Accra, Ghana.
Mike Chisema *Ministry of Health, Lilongwe, Malawi.
Keziah MalmNational Malaria Elimination Programme, Public Health Division, Ghana Health Service, Accra, Ghana.
Lydiah KhalayiNational Vaccines and Immunization Programme, Nairobi, Kenya.
Brenda MhoneMinistry of Health, Lilongwe, Malawi.
Wahjib MohammedNational Malaria Elimination Programme, Public Health Division, Ghana Health Service, Accra, Ghana.
Franklin Asiedu-BekoePublic Health Division, Ghana Health Service, Accra, Ghana.
Adam HajiWorld Health Organization Country Office, Nairobi, Kenya.
Josephine NjorogeWorld Health Organization Country Office, Nairobi, Kenya.
Boston ZimbaWorld Health Organization Country Office, Lilongwe, Malawi.
Esther ChirwaWorld Health Organization Country Office, Lilongwe, Malawi.
Peter O TweneboahWorld Health Organization Country Office, Accra, Ghana.
Jackson SillahTropical and Vector-Borne Diseases Unit, World Health Organization Africa Regional Office, Brazzaville, Congo.
Mgaywa G M D MagafuVaccine-Preventable Diseases Unit, World Health Organization Africa Regional Office, Brazzaville, Congo.
Cynthia BergstromDepartment of Immunization, Vaccines, and Biologicals, World Health Organization, Geneva, Switzerland.
Tracey GoodmanDepartment of Immunization, Vaccines, and Biologicals, World Health Organization, Geneva, Switzerland.
Jenny WalldorfDepartment of Immunization, Vaccines, and Biologicals, World Health Organization, Geneva, Switzerland.
Kristen KelleherDepartment of Immunization, Vaccines, and Biologicals, World Health Organization, Geneva, Switzerland.
Eliane Pellaux-FurrerDepartment of Immunization, Vaccines, and Biologicals, World Health Organization, Geneva, Switzerland.
Mary J HamelDepartment of Immunization, Vaccines, and Biologicals, World Health Organization, Geneva, Switzerland.
Michael R Adjei *World Health Organization Country Office, Accra, Ghana.
Rafiq N A Okine *Global Malaria Programme, World Health Organization, Geneva, Switzerland. okiner@who.int.

Funding

World Health Organization 001
6 · The paper itself

Abstract

backgroundIn October 2021, the World Health Organization (WHO) recommended the RTS,S/AS01

methodsPilot areas were identified, in part, based on local malaria epidemiology. RTS,S was initially introduced in randomly selected areas, while other areas served as comparators until the four-dose schedule vaccine was scaled up following the WHO recommendation in 2021. In Ghana and Kenya, the vaccine was administered at ages 6, 7, 9, and 24 months (Ghana switched to administer the fourth dose at age 18 months in 2023), and Malawi chose a schedule of 5, 6, 7, and 22 months.

resultsVaccination coverage improved over time, reaching about 80% for the first dose and around 75% for the third dose by 2023 in the initial pilot areas. Implementation challenges included an inadequate understanding of age eligibility among healthcare workers during the early phase of introduction, low fourth dose coverage (with a median coverage of 46% in 2023 across the three countries), and disruptions to service delivery caused by disease outbreaks and other natural disasters. Health stakeholders and caregivers attested to the positive impact of introducing the malaria vaccine, including a reduction in malaria hospitalizations and the strengthening of the National Immunization Programme (NIP) through routine immunization refresher training and supportive supervision.

conclusionsThe pilot highlighted lessons for malaria vaccine introduction: (1) clearly outlined roles and responsibilities of key stakeholders including NIP and National Malaria Programme (NMP); (2) appropriate approach to vaccine introduction launch, communication, and demand generation to enhance vaccine uptake; (3) flexibility with dose scheduling to optimize coverage; and (4) updated data collection tools for accurate documentation, and data quality.

Indexed as

Immunization ProgramsMalaria, FalciparumMalaria VaccinesChild, PreschoolGhanaHumansImmunization ScheduleInfantKenyaMalawiPilot ProjectsVaccines, SyntheticMalaria VaccinesRTS,S-AS01 vaccineVaccines, SyntheticGhanaKenyaMalaria preventionMalaria vaccineMalaria vaccine coverageMalaria Vaccine Implementation ProgrammeMalawiNew vaccine introductionPilot implementationRTS,S/AS01

Identifiers

PMID40721790
PMCPMC12305954

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.